These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34196543)

  • 1. Protein Engineering in the Design of Protein-Protein Interactions: SARS-CoV-2 Inhibitors as a Test Case.
    Zahradník J; Schreiber G
    Biochemistry; 2021 Nov; 60(46):3429-3435. PubMed ID: 34196543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
    Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
    Kwarteng A; Asiedu E; Sylverken AA; Larbi A; Sakyi SA; Asiedu SO
    Infect Genet Evol; 2021 Jul; 91():104815. PubMed ID: 33774178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions.
    Chatterjee P; Ponnapati M; Kramme C; Plesa AM; Church GM; Jacobson JM
    Commun Biol; 2020 Nov; 3(1):715. PubMed ID: 33230174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
    Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
    Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.
    Treewattanawong W; Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2021 Nov; 11(1):22202. PubMed ID: 34772947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
    Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
    Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.
    Wei S; Duan S; Liu X; Wang H; Ding S; Chen Y; Xie J; Tian J; Yu N; Ge P; Zhang X; Chen X; Li Y; Meng Q
    Int Immunopharmacol; 2021 Jan; 90():107172. PubMed ID: 33191178
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.
    Capraz T; Kienzl NF; Laurent E; Perthold JW; Föderl-Höbenreich E; Grünwald-Gruber C; Maresch D; Monteil V; Niederhöfer J; Wirnsberger G; Mirazimi A; Zatloukal K; Mach L; Penninger JM; Oostenbrink C; Stadlmann J
    Elife; 2021 Dec; 10():. PubMed ID: 34927585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
    Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.